Immodulon, the immuno-oncology company, will present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event taking place virtually 24-25 March 2021.
The presentation, titled ‘Clinical Biomarker Strategy with a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget’, will be presented at 12:45 CET, March 25, 2021, by its Chief Scientific Officer, Dr. Thomas Kleen.
The presentation will discuss topics including the challenges posed by the identification and validation of various circulatory immunological biomarkers in cancer patients during clinical trials, and the benefits and challenges of using novel technologies and classic immunological biomarkers.
The annual Clinical Biomarkers & CDx Europe Summit brings stakeholders together to fast-track precision medicine through clinically validated biomarkers and companion diagnostics partnerships in Europe. The meeting will cover biomarker discovery through to drug-Dx market penetration, enabling innovation to power pipeline progression. Featuring the latest tools and techniques validating biomarker utility, overcoming patient selection challenges in rare disease, key clinical case-study learnings shaping diagnostic strategy in addition to the core EU focus on navigating a complex regulatory and reimbursement landscape to prevent incoming regulations hindering the delivery of critical drugs to patients in need.
Image credit: Robinson Recalde
